BAUSCH HEALTH AMERICAS, INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- 3.1K
- Market Cap
- -
- Website
- http://www.bauschhealth.com
Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00444158
DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00444210
- Locations
- ๐บ๐ธ
Sanofi-Aventis, Bridgewater, New Jersey, United States
DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00444353
- Locations
- ๐บ๐ธ
Sanofi-Aventis, Bridgewater, New Jersey, United States
Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00434395
Study Evaluating MOA-728 Administered in Healthy Men
Phase 1
Withdrawn
- Conditions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00427258
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00408174
- Locations
- ๐บ๐ธ
West Gastroenterology Medical Group, Los Angeles, California, United States
๐บ๐ธAtlanta Gastroenterology Associates, Atlanta, Georgia, United States
๐บ๐ธUniversity of Illinois at Chicago, Chicago, Illinois, United States
Study of Methylnaltrexone (MNTX) for the Relief of Constipation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT00402038
- Locations
- ๐บ๐ธ
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT00401375
- Locations
- ๐บ๐ธ
Progenics Pharmaceuticals, Tarrytown, New York, United States
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT00401362
- Locations
- ๐บ๐ธ
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00398502
ยฉ Copyright 2024. All Rights Reserved by MedPath